AnaptysBio abandons eczema drug after trial failures; shares nosedive
Biotechnology company AnaptysBio, Inc., specializing in innovative autoimmune disease therapies, announced it will halt development of its atopic dermatitis treatment, ANB032, after the drug failed ... Read More
New hope for eczema sufferers as FDA approves Eli Lilly’s EBGLYSS
Eli Lilly and Company (Lilly) has secured approval from the U.S. Food and Drug Administration (FDA) for its new biologic treatment, EBGLYSS (lebrikizumab-lbkz), for moderate-to-severe ... Read More